TroFuse-055NCT07829783
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change.
- Notable Recruitment opened
- Trial sites expanded: 0 → 10 locations
- Start date changed from estimate of Oct 20, 2026 to Oct 23, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Participants will receive sac-TMT 4 mg/kg by intravenous (IV) infusion every 2 weeks (q2w) for up to 6 doses plus pembrolizumab and berahyaluronidase alfa 790 mg SC every 6 weeks (q6w) for up to 2 doses. CRT (radiotherapy \[RT\] and concurrent chemotherapy) will then be administered to all participants as standard of care per treatment regimens chosen by the investigator. RT will include conventional radiation or hypofractionated radiation to the bladder for up to approximately 6.5 weeks. Concurrent chemotherapy will be administered with RT and will include cisplatin, or 5-fluorouracil (5-FU) + mitomycin C, or capecitabine + mitomycin C, or gemcitabine. Pembrolizumab and berahyaluronidase alfa 790 mg SC will be administered q6w for up to additional 7 cycles as consolidation therapy. Each cycle is 42 days (up to approximately 42 weeks).
CRT (radiotherapy \[RT\] and concurrent chemotherapy) will then be administered to all participants as standard of care per treatment regimens chosen by the investigator. RT will include conventional radiation or hypofractionated radiation to the bladder for up to approximately 6.5 weeks. Concurrent chemotherapy will be administered with RT and will include cisplatin, or 5-fluorouracil (5-FU) + mitomycin C, or capecitabine + mitomycin C, or gemcitabine.
Biologicals: Sac-TMT, Pembrolizumab and Berahyaluronidase alfa
Drugs: Cisplatin, 5-FU, MMC, Capecitabine, Gemcitabine, Rescue Medications
Radiation: Conventional Radiotherapy, Hypofractionated radiotherapy
Sites
10 sites in 2 countries
Ukraine 9, Taiwan 1